Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

AbbVie Inc. researches and develops pharmaceutical products. The Company produces pharmaceutical drugs for specialty therapeutic areas such as immunology, chronic kidney disease, hepatitis C, women"s health, oncology, and neuroscience. AbbVie also offers treatments for diseases including multiple sclerosis, parkinson"s, and alzheimer"s disease.
Website: abbvie.com


  • Good financial results growth rate 19.8% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-10.0%)
  • Dividend yield for the last twelve months 3.4%
  • Free cash flow yield -2.6% (LTM)
  • Share price is 41.8% higher than minimum and 13.3% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (36.7x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $16.1 mln (-0.004% of cap.)

Key Financials (Download financials)

Ticker: ABBV
Share price, USD:  (+0.3%)187.8724
year average price 186.24  


year start price 168.57 2024-06-06

min close price 164.11 2024-07-03

max close price 216.66 2025-03-10

current price 187.87 2025-06-05
Common stocks: 1 768 480 508

Dividend Yield:  3.4%
FCF Yield LTM: -2.6%
EV / LTM EBITDA: 36.7x
EV / EBITDA annualized: 25.3x
Last revenue growth (y/y):  +8.4%
Last growth of EBITDA (y/y):  +31.3%
Historical revenue growth:  +0.5%
Historical growth of EBITDA:  -20.4%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 332 249
Net Debt ($m): 64 755
EV (Enterprise Value): 397 004
EBITDA LTM ($m): 10 815
EV / LTM EBITDA: 36.7x
Price to Book: 54.9x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-06-04zacks.com

Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks

2025-06-03seekingalpha.com

Bert's May 2025 Dividend Income Summary

2025-06-03prnewswire.com

AbbVie Invites People Living with Migraine to Enter the Second Annual AbbVie Migraine Career Catalyst Award™ Contest to Support Their Professional Goals

2025-05-30globenewswire.com

Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) - June 3, 2025 Deadline to Join – Contact Levi & Korsinsky

2025-05-29prnewswire.com

Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for Investors - Contact The Gross Law Firm

2025-05-27seekingalpha.com

Best Dividend Aristocrats For June 2025

2025-05-27accessnewswire.com

Lost Money on Cerevel Therapeutics Holdings, Inc. (ABBV)? Urged to Join Class Action Before June 3, 2025 - Contact Levi & Korsinsky

2025-05-24fool.com

U.S. Pharmaceutical Imports Might Soon Face Tariffs: 3 Stocks That Could Tumble as a Result

2025-05-23prnewswire.com

Levi & Korsinsky Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ABBV

2025-05-22globenewswire.com

Levi & Korsinsky Notifies Shareholders of Cerevel Therapeutics Holdings, Inc. (ABBV) of a Class Action Lawsuit and an Upcoming Deadline
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data